Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals.

R E Weiner1, M L Thakur

  • 1Department of Diagnostic Imaging and Therapeutics, University of Connecticut Health Center, Farmington 06030, USA.

The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)
|May 7, 1999
PubMed
Summary

New radiopharmaceuticals targeting polymorphonuclear leukocytes (PMN) show promise for detecting inflammation and infection. While existing agents have limitations, novel approaches focus on PMN-specific binding for improved diagnostic accuracy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [(64)Cu]DO3A-peptide nucleic acid-peptide nanoparticles.

Cancer biology & therapy·2007
Same author

Receptor-mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours.

Biochemical Society transactions·2007
Same author

Stem cells: a regenerative pharmaceutical.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2006
Same author

99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2006
Same author

Synthesis of novel peptide nucleic acid-peptide chimera for non-invasive imaging of cancer.

Nucleosides, nucleotides & nucleic acids·2005
Same author

Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogene mRNAs.

Nucleosides, nucleotides & nucleic acids·2005

Area of Science:

  • Biomedical imaging
  • Immunology
  • Radiopharmacology

Background:

  • Inflammation involves microcirculation changes, including increased blood flow and endothelial permeability, crucial for radiopharmaceutical delivery.
  • Polymorphonuclear leukocytes (PMN) infiltrate inflammatory sites early, guided by chemo-attractants and adhesion molecule upregulation.
  • Current radiolabeled white blood cell (WBC) agents (e.g., 111In, 99mTc) for infection/inflammation detection have limitations.

Purpose of the Study:

  • To explore novel radiopharmaceutical agents targeting PMN for improved inflammation and infection detection.
  • To overcome limitations associated with current radiolabeled WBC imaging techniques.

Main Methods:

  • Investigated radiopharmaceuticals designed to bind to PMN at inflammatory sites.

Related Experiment Videos

  • Explored targeting PMN-associated antigens or receptors on activated PMN.
  • Examined four specific monoclonal antibodies (CEA-47, BW 250/183, IMMU-NN3, MCA-480) for abscess/infection detection in human studies.

    • Main Results:

    • Monoclonal antibodies CEA-47, BW 250/183, IMMU-NN3, and MCA-480 have been extensively evaluated.
    • These agents aim to improve diagnostic accuracy by targeting PMN, a key component of inflammatory responses.

    Conclusions:

    • Development of PMN-targeted radiopharmaceuticals offers a promising strategy to enhance the detection of inflammation and infection.
    • Further research into these novel agents is warranted to overcome existing diagnostic limitations.